X4 Pharmaceuticals gets positive FDA input on 4WARD Phase 3 trial
FDA agreed to a reduced sample size for X4 Pharmaceuticals’ Global 4WARD Phase 3 chronic neutropenia trial. Enrollment is expected to complete by year-end 2026, with topline data due in H1 2028.
FDA has agreed to a reduced sample size for the global 4WARD Phase 3 chronic neutropenia trial. X4 Pharmaceuticals said it now expects enrollment to be completed by year-end 2026, with topline data in H1 2028. BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals NASDAQ:XFOR, a company focused on improving the lives of people w…